Terry D. Hinds, Jr., Ph.D.
|
|
Assistant Professor, Department of Physiology and Pharmacology Phone: (419) 383-4465 |
During a reception held, May 3, 2018 in Dr. Gaber's home, Dr. Hinds was one of 25
faculty members to be recognized for outstanding contributions to University scholarship
and creative activity. The Committee was impressed with his high quality journal articles,
including recognition as the paper of the week in the Journal of Biological Chemistry and having the cover illustration in the journal Hormones and Cancer.
Research Interests:
My lab focuses on the involvement of the heme oxygenase (HO) system and nuclear receptors
in metabolic diseases, which includes obesity and diabetes as well as cancer. The
HO system maintains metabolic balance by signaling to biliverdin reductase that produces
the antioxidant, bilirubin. My lab looks at the how HO, bilirubin, and nuclear receptors
signal for balance in metabolic disorders. We are currently studying how bilirubin
can aid the nutrient and lipid sensing nuclear receptors, the PPARs (PPAR alpha, PPAR
gamma, and PPAR delta), in the maintenance of metabolic homeostasis. Other nuclear
receptors are stress sensing, such as the glucocorticoid receptors (GRalpha and GR
beta), which regulate the immune system balance and glucose production during times
of stress. Together, the PPARs and GRs regulate the balance of lipids and glucose
as well as maintain growth of cancer cells.
Current studies:
Project 1: We are working on drug targeting of the heme oxygenase system in the prevention of
obesity and the link between fat tissue in obesity-induced hypertension. Diet induced
obesity results in elevated levels of glucose and fatty acids in blood, liver and
fat tissues, resulting in the enhanced production of reactive oxygen species (ROS).
The oxidative stress magnifies the adverse effects of obesity by inducing inflammation
of tissues, leading to the development of non-alcoholic fatty liver disease (NAFLD)
as well as vascular dysfunction.
Project 2: We are looking at the role of the glucocorticoid receptors in prostate and bladder
cancer. This is a clinical investigation in collaboration with the UT Department
of Urology and Department of Pathology, which includes analysis of human specimens
taken from patients at the University of Toledo Health Center. We have been screening
human cancer samples for expression of the GR isoforms, in which, one may be linked
to metastasis. In these studies, we are also using human cancer cells to understand
the involvement of the receptors in cancer and drug targeting. Interestingly, we
have discovered that metabolic growth factors such as insulin and epidermal growth
factor enhance the expression of the receptor and lead to exacerbated growth. We
are currently looking at drugs that can inhibit the function of the GR isoform that
leads to growth.
Project 3: In our newest study, we are analyzing the biliverdin reductase (BVRA and BVRB) in
metabolic disorders such as obesity and diabetes, and potential drug targeting of
the enzymes. On this project, we are collaborating with the University of Mississippi
Medical Center as well as the Center for Drug Design and Development, which are building
us new drug compounds that can target the BVR isozymes as well as nuclear receptors
in the prevention of obesity and diabetes. This project is of novel drug design that
may lead to a new class of drugs known as THin Molecules.
Appointments:
2016-Assistant Professor, Tenure Track, Department of Urology, University of Toledo
2014-Graduate Faculty Associate, Department of Kinesiology, University of North Carolina
at Charlotte
2013 - Assistant Professor, Tenure Track, Physiology & Pharmacology, University of
Toledo
2012 - Instructor, Organ Systems course in Physiology & Pharmacology, University of
Toledo
2010 - Postdoctoral Fellow, Physiology & Pharmacology, University of Toledo
2007 - Guest lecturer for Methods in Molecular Biology course, Medical University
of Ohio
2004 - Anatomy and Physiology I & II, Adjunct Instructor, Shawnee State University
Awards and Commendations:
2017 Dean's Award for Research Excellence in the New Investigator category,
UT
2016 deArce-Koch Memorial Fund Award
2016 Faculty Innovator Award, Department of Physiology and Pharmacology,
UT
2015 President of the Ohio Physiological Society
2014 Research Scientist Development Award (K01) NIH/NHLBI
2014 NIH LRP Award for Health Disparities Research
2013 NIH NHLBI program, PRIDE-Functional and Applied Genomic of Blood Disorders
2010 Selected for Oral Presentation in “Hot topics of Physiology”, Keystone Symposia,
Nuclear Receptors: Signaling, Gene Regulation and Cancer,
Keystone, CO
2010 Cancer, Genetics, and Signaling (CGS) Group at the National Cancer
Institute-Frederick.
Selected in Top 10 at the NIH Graduate Student Research Festival
(200 total).
2010 Abstract Award, Endocrine Society National Meeting, San Diego,
CA
2009-10 Ruth L. Kirschstein National Research Service Award (NRSA), NIDDK,
NIH
2001 Thinker of the Year Award Recipient, Civic Development Group
Patents:
Patent - D2009-23– Provisional Patent Application
For: “Glucocorticoid Receptor Beta in Mice”
Inventors: Terry D. Hinds, Jr. (50%) and Edwin R. Sanchez (50%)
Ser. No. 61/333,708 provisional patent filed May 11, 2010
MST File No.: 1-50554
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC
*Provisional Patent
Patent - D2010-63– Provisional Patent Application
For: “Methods and Compositions for Treating Dyslipidemia and Obesity using Protein
Phosphatase 5 as a Drug Target.”
Inventors: Terry D. Hinds, Jr. (50%) and Edwin R. Sanchez (50%)
Ser. No. 61/454,928 provisional patent filed March 21, 2011
MST File No.: 1-52813
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC
Patent - D2016-49 – Provisional Patent Application
For: “Targeting of human glucocorticoid receptor beta in cancer.”
Inventors: Terry D. Hinds, Jr. (90%) and Lucien McBeth (10%)
US Serial No.: 62/306,209 filed March 10, 2016
MST File No.: 1-57720
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC
Patent - D2016-29 – Provisional Patent Application
For: “Thin Molecules for the Treatment of Obesity and Type II Diabetes.”
Inventors: Terry D. Hinds, Jr. (70%), Chris Trabbic (20%), and David Stec (10%)
US Serial No.: 62/301,134 filed February 29, 2016
MST File No.: 1-57768
LAW OFFICES OF MACMILLAN, SOBANSKI & TODD, LLC
Licensing:
Resource: Mouse Glucocorticoid Receptor beta Polyclonal Antibody
Inventors: Terry D. Hinds, Jr. and Edwin R. Sanchez
http://utoledo.technologypublisher.com/technology/11366
Editorial Board Member:
Cell Stress 2016—present (Editorial Board includes 5 Nobel prize winners and 33 members
of the National Academy of Sciences)
Nuclear Receptor Research 2016—present
International Journal of Clinical Endocrinology and Metabolism 2015—present
Annals of Obesity & Disorders 2015—present
International Journal of Clinical Pharmacology and Toxicology 2015—present
Frontiers in Pharmacology - Drug Metabolism and Transport Specialty Section 2015—present
Diabetes Research - Open Journal 2014—present
Obesity Research - Open Journal 2014—present